BMS’s Breyanzi is the first CAR-T Cell Therapy approved for two types of leukemia
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) has made history as the first CAR-T therapy approved for two types of leukemia: relapsed or refractory large B-cell lymphoma (LBCL) and relapsed or refractory mantle cell lymphoma (MCL). CAR-T (chimeric antigen receptor T-cell) therapy is a revolutionary type